- Home
- LXP vs LIVN Comparison
LXP vs LIVN Comparison
Compare LXP & LIVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LXP | LIVN |
|---|---|---|
| Founded | 1993 | 1987 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 4.3B |
| IPO Year | 1996 | 2015 |
Fundamental Metrics
Financial Performance| Metric | LXP | LIVN |
|---|---|---|
| Price | $61.03 | $76.68 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 11 |
| Target Price | $59.24 | ★ $90.55 |
| AVG Volume (30 Days) | ★ 793.5K | 604.7K |
| Earning Date | 10-29-2026 | 11-04-2026 |
| Dividend Yield | ★ 4.59% | N/A |
| EPS Growth | ★ 1300.00 | N/A |
| EPS | N/A | ★ 2.33 |
| Revenue | ★ $350,228,000.00 | N/A |
| Revenue This Year | $0.79 | $9.65 |
| Revenue Next Year | $5.25 | $7.11 |
| P/E Ratio | ★ N/A | $33.12 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $9.02 | $48.82 |
| 52 Week High | $61.61 | $85.76 |
Technical Indicators
Market Signals| Indicator | LXP | LIVN |
|---|---|---|
| Relative Strength Index (RSI) | 61.55 | 48.21 |
| Support Level | $60.73 | $74.69 |
| Resistance Level | $61.17 | $82.39 |
| Average True Range (ATR) | 0.08 | 2.00 |
| MACD | -0.02 | 0.18 |
| Stochastic Oscillator | 81.82 | 69.17 |
Price Performance
Historical ComparisonAbout LXP LXP Industrial Trust (Maryland REIT)
LXP Industrial Trust is a real estate investment trust principally involved in the ownership of equity and debt investments in single-tenant properties and land throughout the United States. The majority of the revenue is earned through rental revenue.
About LIVN LivaNova PLC
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives approximately half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.